LIBI-Diagnostics

Introduction: • LIBI-Diagnostics is a gene-biomarker start-up for early detection of cancer, powered by

the next-generation bio-liquid test.

• The venture was recently accepted into the Ministry of Economy's accelerator program

- MaofTech.

• Funding and development plans were submitted to the venture by Albert Einstein

College of Medicine in New York.

Developing a non-invasive method to detect and quantify AURKA-gene mRNA over-

expression by RNA-FISH (fluorescent in situ hybridization) presented in voided Urine

samples.

Technological breakthrough:

Mission Statement:

Our mission is to provide doctors and patients with critical data from body fluids that have

not been technically available to date and can save many patients' lives and even change the

face of medicine.

& CEO:Co-FounderDavid Risin Attorney.

Master of Real Estate.

(Technion, Israel Institute of Technology)

Tel: 050-6270399

Email: risin75@gmail.com

& CMO:Co-FounderDr. Ayelet Ben Barak

Senior physician in Pediatric

Hematology-Oncology.

Former head of the hematology unit at Rambam

Hospital.

M.D.

(Technion, Israel Institute of Technology)

Principal Investigator:

Ganjam V. Kalpana, Ph.D.

Mark Trauner Faculty Scholar in Neuro-Oncology

Professor, Department of Genetics

Professor, Department of

Microbiology and Immunology.

Albert Einstein College of Medicine1300 Morris Park Ave., Ullman 821

Bronx, New York, 10461

Tel: 1-718-430-2354

Fax: 1-718-430-8778

https://www.einstein.yu.edu/faculty/6576/ganjam-kalpana/

Email: ganjam.kalpana@einstein.yu.edu

Market potential• It is a body fluid test, without the need for tumor tissue.

• The test is needed for medical follow up of cancer patients who are in remission and allow early detection of recurrence.

• The test allows anyone to perform cancer screening that can diagnose cancer at the earliest stage.

R&D + Funding• Year 1 - Optimization of methods in normal voided urine samples mixed

with rhabdoid tumors cell lines - $200K (University requirements).

• Year 2 - Optimization of methods in voided urine samples from

patients - $400K (University requirements).

• Year 1 + 2 - Company formation, patent registration, management

and advertising - $500K.

Competitors:• Freenome inc - is a biotechnology company that develops a multiomics

platform for early detection of cancer – Total funding: $237.6M

• GRAIL - is a healthcare company whose mission is to detect cancer early,

when it can be cured - Total funding: $1.6B

We can do it